GL1X · GenesisL1 explorer

MolNFT v1 · #112870 · protein

Discovery of nvp-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in P53WT tumors: HDM2 (MDM2) complexed with nvp-CGM097

4ZYF · E3 ubiquitin-protein ligase MDM2: “Discovery of nvp-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in…”. X-ray diffraction, 2 ligands (4T4, CL), 1 pocket (best druggability 0.48). MolNFT v1…

PDB
4ZYF
Type
protein
Length
93 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
E3 ubiquitin-protein ligase MDM2
EC
6.3.2.-
UniProt
Q00987
Ligands
4T4, CL
Pockets
1 · best druggability 0.48

Structure

x-ray diffraction · 1 distinct chain · 46% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AE3 ubiquitin-protein ligase MDM2 (EC 6.3.2.-)protein9346% helix, 17% strandQ00987

Ligands and binding sites

  • 4T4 · (S)-1-(4-chlorophenyl)-7-isopropoxy-6-methoxy-2-(4-(methyl(((1r,4S)-4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl)methyl)amino)phenyl)-1,2-dihydroisoquinolin-3(4H)-one · ligand · chains A
  • CL · Chloride ion · ion · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11800.480.75244T4

Compared structures

  • 4ZYF · Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.